Stock Analysis

AVITA Medical reported third quarter 2026 results on 5 November 2026. Total revenue rose 53% year on year and 20% sequentially to $26.1 million, driven by RECELL and increasing use of Cohealyx.

Neuren reported on 5 November 2026 that Q3 2026 DAYBUE net sales were US$140 million, up 39% on Q3 2025, driven by uptake of DAYBUE STIX.

Patrys released its quarterly activities report on 29 October 2026. The company said human research ethics approval was secured and first participants were dosed in the RLS-2202 Phase 1a trial at CMAX.

On 27 October 2026, Argent announced a 10-year exclusive worldwide licensing agreement with Thai Phytomed International Co., Ltd. for the commercial development of four proprietary cannabis genotypes.

Buxton released its quarterly activities report for the period ending 30 September 2026 on 26 October 2026. The company secured 14.2 km² of 100%-owned tenure at Arivaca in Arizona. Reconnaissance sampling there returned up to 6.21% copper and 1,355 g/t silver from historic mine-dump …

Cokal released itsQuarterly Reportfor the three months to 30 September 2026 on 30 October 2026.Miningactivities were significantly constrained during the quarter while Phase 2 RKAB approval was pending. That approval was received in mid-September 2026.

Fulcrum released its quarterly activities report for the quarter ended 30 September 2026 on 30 October 2026. The company reported a large-scale maiden mineral resource estimate for Alkali Flats, delivered within a year of discovery.